Generation Bio is innovating genetic medicines to provide durable, redosable treatments for people living with rare and prevalent diseases. The company’s non-viral platform incorporates a novel DNA construct called closed-ended DNA, or ceDNA; a unique cell-targeted lipid nanoparticle delivery system, or ctLNP; and a highly scalable capsid-free manufacturing process that uses its proprietary cell-free rapid enzymatic synthesis, or RES, to produce ceDNA. The platform is designed to enable multi-year durability from a single dose, to deliver large genetic payloads, including multiple genes, to specific tissues, and to allow titration and redosing to adjust or extend expression levels in each patient. RES has the potential to expand Generation Bio’s manufacturing scale to hundreds of millions of doses to support their mission to extend the reach of genetic medicine to more people, living with more diseases, around the world.
0
Total investors
0
Early stage
0
Mid stage
0
Late stage
2016
Founded
Investors
0 investors
All
Early stage
Mid stage
Late stage
No investors in this category
Frequently asked questions
When was Generation Bio founded?
Generation Bio was founded in 2016.
What industry is Generation Bio in?
Generation Bio operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Generation Bio based?
Generation Bio is headquartered in Cambridge, United States.
Find investors for your startup like Generation Bio
Gritt sends AI-personalised outreach to each investor — from your Gmail
